Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF Priming in Older Adults with AML
NCT04446052Phase 3Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- May 1993
- Primary completion
- Jul 2002
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing GM-CSF priming with Placebo (2 arms). Primary endpoint: Complete Remission Rates at 3 years. Started May 1993; status: completed.
02
Drugs
sargramostim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04446052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04446052.